Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Abstract Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Adis, Springer Healthcare,
2019-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|